Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells.

Barcz, Ewa; Sommer, Ewa; Janik, Piotr; Marianowski, L; Skopińska-Różewska, Ewa

doi:10.3892/or.7.6.1285

Cited by 22 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This purine nucleoside is present in the extracellular fluid of solid tumors as a result of tissue hypoxia (Mujoomdar et al, 2003;Spychala et al, 2004). It provides a supportive environment that benefits malignancy and may include protection against ischemia, stimulation of tumor growth (Spychala et al, 2004), tumor cell migration (Woodhouse et al, 1998), angiogenesis (Barcz et al, 2000), as well as suppression of immune responses (Hoskin et al, 1994).…”

Section: Introductionmentioning

confidence: 99%

Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: Molecular identification, kinetic characterization and biochemical properties

Buffon

Ribeiro

Wink³

et al. 2007

Life Sciences

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: Molecular identification, kinetic characterization and biochemical properties

Buffon

Ribeiro

Wink³

et al. 2007

Life Sciences

View full text Add to dashboard Cite

“…A combination of zoledronic acid and fluvastatin has been claimed to have activity against ovarian (and breast) cancer based on this assay [427]. A 2 receptor antagonism inhibits angiogenic activity of human ovarian cancer cells [428]. Variants of the RB1 gene have been implicated as risk factors for invasive ovarian cancer [429].…”

Section: Ovarian Cancermentioning

confidence: 99%

Purinergic signalling and cancer

Burnstock

Virgilio

2013

Purinergic Signalling

272

265

View full text Add to dashboard Cite

Receptors for extracellular nucleotides are widely expressed by mammalian cells. They mediate a large array of responses ranging from growth stimulation to apoptosis, from chemotaxis to cell differentiation and from nociception to cytokine release, as well as neurotransmission. Pharma industry is involved in the development and clinical testing of drugs selectively targeting the different P1 nucleoside and P2 nucleotide receptor subtypes. As described in detail in the present review, P2 receptors are expressed by all tumours, in some cases to a very high level. Activation or inhibition of selected P2 receptor subtypes brings about cancer cell death or growth inhibition. The field has been largely neglected by current research in oncology, yet the evidence presented in this review, most of which is based on in vitro studies, although with a limited amount from in vivo experiments and human studies, warrants further efforts to explore the therapeutic potential of purinoceptor targeting in cancer.

show abstract

“…The natural ligand adenosine induces a direct anti-proliferative effect on various tumor cell types at micromolar (μM) concentrations. Indirectly, it affects tumor development via its capability to modulate cytokine release, cell migration, angiogenesis, and chemotaxis (Woodhouse et al, 1998; Barcz et al, 2000; Madi et al, 2004). Moreover, adenosine induces activation or suppression of T killer or natural killer cells, which affects tumor cell development (Harish et al, 2003).…”

mentioning

confidence: 99%

CF102 an A₃ adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver

Cohen

Stemmer

Zozulya

et al. 2011

Journal Cellular Physiology

View full text Add to dashboard Cite

The Gi protein-associated A3 adenosine receptor (A3AR) is a member of the adenosine receptor family. Selective agonists at the A3AR, such as CF101 and CF102 were found to induce anti-inflammatory and anti-cancer effects. In this study, we examined the differential effect of CF102 in pathological conditions of the liver. The anti-inflammatory protective effect of CF101 was tested in a model of liver inflammation induced by Concanavalin A (Con. A) and the anti-cancer effect of CF102 was examined in vitro and in a xenograft animal model utilizing Hep-3B hepatocellular carcinoma (HCC) cells. The mechanism of action was explored by following the expression levels of key signaling proteins in the inflamed and tumor liver tissues, utilizing Western blot (WB) analysis. In the liver inflammation model, CF102 (100 μg/kg) markedly reduced the secretion of serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase in comparison to the vehicle-treated group. Mechanistically, CF102 treatment decreased the expression level of phosphorylated glycogen synthase kinase-3β, NF-κB, and TNF-α and prevented apoptosis in the liver. This was demonstrated by decreased expression levels of Fas receptor (FasR) and of the pro-apoptotic proteins Bax and Bad in liver tissues. In addition, CF102-induced apoptosis of Hep-3B cells both in vitro and in vivo via de-regulation of the PI3K-NF-κB signaling pathway, resulting in up-regulation of pro-apoptotic proteins. Taken together, CF102 acts as a protective agent in liver inflammation and inhibits HCC tumor growth. These results suggest that CF102 through its differential effect is a potential drug candidate to treat various pathological liver conditions.

show abstract

Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells.

Cited by 22 publications

References 0 publications

Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: Molecular identification, kinetic characterization and biochemical properties

Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: Molecular identification, kinetic characterization and biochemical properties

Purinergic signalling and cancer

CF102 an A₃ adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver

Contact Info

Product

Resources

About

Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells.

Cited by 22 publications

References 0 publications

Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: Molecular identification, kinetic characterization and biochemical properties

Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: Molecular identification, kinetic characterization and biochemical properties

Purinergic signalling and cancer

CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver

Contact Info

Product

Resources

About

CF102 an A₃ adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver